Viatris Inc. (NASDAQ:VTRS) became the subject of a securities fraud class action lawsuit filed in the U.S. District Court for ...

The FDA has designated the viral vector rAAVrh74, which Sarepta Therapeutics, Inc. (NASDAQ:SRPT) uses in its gene therapy ...

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals ...

The FDA's platform technology program aims to improve ... SRPT is currently trading at $39.34, up $0.46 or 1.19 percent on the Nasdaq. The views and opinions expressed herein are the views and ...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for priority review its New Drug Application (NDA) for TransCon CNP (navepegritide ...

Amylyx Pharmaceuticals (NASDAQ:AMLX) said on Tuesday that the U.S. FDA has granted fast track status to its antisense RNA, ...

The FDA is set to decide by June 10 ... views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York, with ...

ImmunityBio (NASDAQ:IBRX) said on Monday that the U.S. FDA has approved expanded access for its Cancer BioShield platform, ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the surgical equipment & consumables - specialty stocks ...

The U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for ziftomenib, an investigational ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...